Product Code: GDHC501DFR
Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.
Xeljanz (tofacitinib, formerly known as tasocitinib) is an oral, small-molecule inhibitor of JAK3 developed by Pfizer. Xeljanz is a first-in-class drug that was approved for the treatment of RA in the US in 2012, and in Japan in 2013. It is also in development for the treatment of psoriasis (as a topical and oral formulation), psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, atopic dermatitis, and juvenile idiopathic arthritis in the seven major markets (7MM; US, 5EU, and Japan).
- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Xeljanz (tofacitinib) including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Xeljanz (tofacitinib) for the top 2 countries from 2013 to 2023.
- Sales information covered for the US and Japan.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Xeljanz (tofacitinib) performance.
- Obtain sales forecast for Xeljanz (tofacitinib) from 2013-2023 in top 2 countries (the US and Japan).
Table of Contents
1. Table of Contents
- 1.1. List of Tables
- 1.2. List of Figures
- 2.1. Catalyst
- 2.2. Related Reports
- 2.3. Upcoming Related Reports
3. Disease Overview
- 3.1. Etiology and Pathophysiology
- 3.1.1. Etiology
- 3.1.2. Pathophysiology
- 3.2. Symptoms
- 3.3. Prognosis
- 3.4. Quality of Life
4. Disease Management
- 4.1. Diagnosis and Treatment Overview
- 4.1.1. Diagnosis
- 4.1.2. Treatment Guidelines
- 4.1.3. Leading Prescribed Drugs for the Treatment of RA
- 4.1.4. Clinical Practice
5. Competitive Assessment
6. Xeljanz (tofacitinib)
- 6.1. Overview
- 6.2. Efficacy
- 6.3. Safety
6.4. SWOT Analysis
- 7.1. Bibliography
- 7.2. Abbreviations
- 7.3. Methodology
- 7.4. Forecasting Methodology
- 7.4.1. Diagnosed RA Patients
- 7.4.2. Percentage of Drug-Treated Patients
- 7.4.3. General Pricing Assumptions
- 7.4.4. Individual Drug Assumptions
- 7.4.5. Generic and Biosimilar Erosion
- 7.5. Primary Research - KOLs Interviewed for This Report
- 7.6. Primary Research - Prescriber Survey
- 7.7. About the Authors
- 7.7.1. Analyst
- 7.7.2. Reviewer
- 7.7.3. Therapy Area Director
- 7.7.4. Global Head of Healthcare
- 7.8. About GlobalData
- 7.9. Disclaimer
List of Tables
- Table 1: Symptoms of RA
- Table 2: 1987 ACR Diagnostic Criteria for RA
- Table 3: 2010 ACR/EULAR Diagnostic Criteria for RA
- Table 4: Treatment Guidelines for RA Used by Each Country in the 10MM
- Table 5: ACR 2012 Criteria for RA Remission and Low/Moderate/High Disease Activity
- Table 6: EULAR 2013 Criteria for RA Remission
- Table 7: Most Prescribed Biologics for RA (After csDMARDs) in the Global Markets, 2014
- Table 8: Leading Branded Treatments for RA 2014
- Table 9: Product Profile - Xeljanz
- Table 10: ORAL Standard ACR20 Responses for Tofacitinib vs. Humira and Placebo at Month 6
- Table 11: ORAL Step ACR20, 50, and 70 Responses for Xeljanz vs. Placebo at Month 6
- Table 12: Xeljanz SWOT Analysis, 2014
- Table 13: Global Sales Forecasts ($m) for Xeljanz, 2013-2023
- Table 14: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
- Figure 1: Normal Synovial Joint and Synovial Joint with RA
- Figure 2: Cellular and Cytokine Targets for the Current RA Drugs
- Figure 3: Disease Management Flowchart for Early RA - ACR 2012
- Figure 4: Disease Management Flowchart for Established RA - ACR 2012
- Figure 5: Flowchart for the Management of RA - EULAR 2013